National Institute of Allergy and Infectious Diseases (NIAID): HIV Infections trials

The registry lists 728 HIV Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 9 are open to participants now and 104 have results posted.

Phase 1 327Phase 2 183Phase 3 57Phase 4 7No phase 195(a study in two phases counts in both)

Studies

Page 5 of 8. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsCompletedNCT00006066Phase 1
• A Comparison of Two Anti-HIV Treatment PlansCompletedNCT00005915
• Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedNCT00005779Phase 1
• Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNCT00005762Not applicable
• Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug CombinationCompletedNCT00005758Phase 3
• Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV DrugsCompletedNCT00005673Phase 1
• Observing Patients With Early HIV InfectionCompletedNCT00005020
• Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV DrugsCompletedNCT00004855Not applicable
• The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIVCompletedNCT00004735Not applicable
• Once-Daily Drug Regimen for HIV-Infected PatientsCompletedNCT00001968Phase 1
• Intermittent Versus Continuous Medication in the Treatment of HIVCompletedNCT00001967Phase 4
• Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral TherapyCompletedNCT00001899
• Drug Interactions Among Anti-HIV AgentsCompletedNCT00001766Phase 1
• Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex InfectionCompletedNCT00001763Phase 1
• Magnetic Resonance Imaging of the Face and BonesCompletedNCT00001762
• Continued Antiretroviral Therapy With Abacavir, Amprenavir and EfavirenzCompletedNCT00001758Phase 2
• Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected PatientsCompletedNCT00001650
• White Blood Cell Infusions to Treat HIV InfectionCompletedNCT00001647Phase 1
• Voriconazole vs. Amphotericin B in the Treatment of Invasive AspergillosisCompletedNCT00001646Phase 3
• Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV InfectionCompletedNCT00001644Phase 1
• Fluconazole Prophylaxis of Thrush in AIDSCompletedNCT00001542Phase 4
• The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In VivoCompletedNCT00001540
• Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative VolunteersCompletedNCT00001538Phase 1
• Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor AntagonistCompletedNCT00001475Phase 2
• Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study ModificationsCompletedNCT00001409Phase 1
• Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected PatientsCompletedNCT00001357Phase 2
• Interleukin-2 Therapy for HIV Infection - Supplemental ProceduresCompletedNCT00001354Phase 2
• Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin PairsCompletedNCT00001353
• A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected PatientsCompletedNCT00001282Phase 2
• A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV VaccineCompletedNCT00001136Phase 1
• A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their InfantsCompletedNCT00001135Phase 3
• Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or SaquinavirCompletedNCT00001133Phase 1
• Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug CombinationCompletedNCT00001132Phase 2
• Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive PatientsCompletedNCT00001131Not applicable
• Identifying Emergency Room Patients Who Have Recently Been Infected With HIVCompletedNCT00001130
• A Study of Two Adherence Plans to Help HIV-Positive Patients Take Their Medications CorrectlyCompletedNCT00001129Not applicable
• Treatment of Chronic Cryptosporidiosis in AIDS PatientsTerminatedNCT00001128Not applicable
• A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications CorrectlyCompletedNCT00001122Phase 2
• A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1CompletedNCT00001121
• Study of a New Anti-HIV Drug, T-20, in HIV-Infected ChildrenCompletedNCT00001118Phase 1
• The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken ZidovudineCompletedNCT00001112Phase 1
• A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected ChildrenCompletedNCT00001111Not applicable
• Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected PatientsCompletedNCT00001110Not applicable
• A Blood Test to Look at Cells of the Immune System in Healthy ChildrenCompletedNCT00001109
• A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual DosesCompletedNCT00001108Phase 1
• A Study of Zidovudine in HIV-Infected Pregnant Women and Their ChildrenCompletedNCT00001106Phase 1
• The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive PatientsCompletedNCT00001102
• Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune SystemsCompletedNCT00001097
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected AdultsCompletedNCT00001096Phase 1
• A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken AmprenavirCompletedNCT00001095Phase 2
• A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected PatientsWithdrawnNCT00001094Phase 2
• Outcomes of Anti-HIV Therapy During Early HIV InfectionCompletedNCT00001093
• The Biology of HIV TransmissionCompletedNCT00001092
• Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and TeensCompletedNCT00001091Phase 1
• A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected VolunteersCompletedNCT00001090Phase 1
• A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult VolunteersCompletedNCT00001088Phase 1
• The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV DrugsCompletedNCT00001087Phase 2
• A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected PatientsCompletedNCT00001086Phase 2
• A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected PatientsCompletedNCT00001085Phase 2
• A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected PatientsCompletedNCT00001084Phase 2
• Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV DrugsCompletedNCT00001083Phase 2
• Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected IndividualsWithdrawnNCT00001080Not applicable
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine SchedulesCompletedNCT00001076Phase 1
• The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected PatientsCompletedNCT00001075Not applicable
• The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected PatientsCompletedNCT00001074Phase 1
• Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical TumorsCompletedNCT00001073Phase 3
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult VolunteersCompletedNCT00001072Phase 1
• A Study of Stem Cells and FilgrastimCompletedNCT00001071Not applicable
• The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected PatientsWithdrawnNCT00001070Not applicable
• A Study of Two Methods of Determining When to Begin or Change Anti-HIV TreatmentTerminatedNCT00001069
• The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV DrugsCompletedNCT00001067Phase 2
• A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected ChildrenCompletedNCT00001066Phase 2
• A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3TerminatedNCT00001064Not applicable
• The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 WeeksCompletedNCT00001063Phase 2
• A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected PersonsCompletedNCT00001060Phase 1
• The Effectiveness of Two Anti-HIV Treatments in HIV-Infected PatientsCompletedNCT00001057Phase 2
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg DoseCompletedNCT00001056Phase 1
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult VolunteersCompletedNCT00001055Phase 1
• A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative SubjectsCompletedNCT00001053Phase 1
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy AdultsCompletedNCT00001052Phase 1
• Study of Women Who Have AIDSTerminatedNCT00001050
• A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIVCompletedNCT00001049Phase 1
• Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)WithdrawnNCT00001046Phase 1
• Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the DiseaseCompletedNCT00001045Phase 2
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.CompletedNCT00001044Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001043Phase 1
• A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected IndividualsCompletedNCT00001042Phase 1
• Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)CompletedNCT00001041Phase 1
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsCompletedNCT00001038Phase 3
• A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001037Phase 1
• The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV InfectionsCompletedNCT00001035Phase 1
• The Treatment of Tuberculosis in HIV-Infected PatientsCompletedNCT00001033Phase 3
• A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZTCompletedNCT00001032Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy AdultsCompletedNCT00001031Phase 2
• A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the PastCompletedNCT00001029Phase 2
• Evaluation of Patients Who Have Not Had Success With ZidovudineCompletedNCT00001025Phase 2
• The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDSCompletedNCT00001024Not applicable
• A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected PatientsCompletedNCT00001022Phase 3
• A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)CompletedNCT00001021Phase 1
• A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)CompletedNCT00001020Phase 1